Faculty & Staff Details

	Name:	Paul Trippier
	Position:	Assistant Professor
	Email:	paul.trippier@ttuhsc.edu
	Bio	Dr. Trippier joined the Pharmaceutical Sciences faculty in September 2012. He received his undergraduate degree with first class honors in Chemistry and Toxicology at the University of Hull (UK) undertaking undergraduate research on the design and synthesis of novel Angiotensin-converting enzyme inhibitors. Dr. Trippier received his Ph.D. in 2007 from the University of Oxford (UK) working on the total and diversity orientated synthesis of bioactive natural products. He completed postdoctoral research at The Welsh School of Pharmacy, Cardiff University (UK) in antiviral and anticancer medicinal chemistry. He joins the School of Pharmacy from Northwestern University, IL where he conducted research in the laboratory of Richard B. Silverman on the synthesis and intracellular target identification of potential new therapeutics for the treatment of neurodegenerative disease.

Education:

M.Chem Chemistry and Toxicology, University of Hull, 2000
Ph. D. Organic Chemistry, University of Oxford, 2007
Postdoctoral Associate Welsh School of Pharmacy, Cardiff University, 2010
Postdoctoral Fellow Northwestern University, 2012

Research Interests:

Research in the Trippier lab involves the use of state of the art organic and medicinal chemistry techniques combined with chemical biology approaches to design, synthesis and evaluate new molecules for the treatment of human disease and to probe biological systems with a particular emphasis on diseases of the pediatric population.

Specific areas of interest include:
- Drug Discovery: Design and synthesis of compounds that modulate the tumor-stromal cell interaction as novel compounds for the treatment of drug resistant cancers.
- Drug Discovery: Evaluation of small molecule kinase inhibitors as potential therapeutics in pediatric neuromuscular disorders.
- Chemical neuroscience: Discovery of compounds that trigger axon regeneration and their utilization as chemical probes to further our understanding of the brain.

Memberships:
2012-Present Member of the American Association of Colleges of Pharmacy
2009-Present Member of the American Chemical Society
2004-Present Member of the Royal Society of Chemistry

Publications:

Selected Recent Publications:

Paul C. Trippier, Kristin J. Labby, Dustin D. Hawker, Jan Mataka, and Richard B.Silverman; Target- and Mechanism-Based Therapeutics for Neurodegenerative Diseases: Strength in Numbers. J. Med. Chem. 2013, In Press. DOI: 10.1021/jm3015926

Paul C. Trippier; Synthetic Strategies for the Biotinylation of Bioactive Small Molecules. ChemMedChem 2013, 8, 190-203.

Paul C. Trippier, Radhia Benmohammed, Donald R. Kirsch, and Richard B. Silverman; Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1. Bioorg. Med. Chem. Lett. 2012, 22, 6647-6650.

Plamen Angelov, Sonia Chau, Paul J. Fryer, Mark G. Moloney and Paul C. Trippier; Biomimetic synthesis, antibacterial activity and structure activity properties of the pyroglutamate core of oxazolomycin. Org. Biomol. Chem. 2012, 10, 3472-3485.

Paul C. Trippier; “Bis(cyclopentadienyl)dimethyltitanium – second update” in e-EROS Encyclopedia of Reagents for Organic Synthesis. 2012, Eds: Crich, D.; Charette, A. B.; Fuchs, P. L.; Rovis, T. John Wiley & Sons Ltd. Chichester, UK.

Lada Klaic, Paul C. Trippier, Rama K. Mishra, Richard I. Morimoto and Richard B. Silverman; Remarkable stereoselective conjugate additions to the Hsp90 inhibitor Celastrol. J. Am. Chem. Soc. 2011, 133, 19634-19637.


Selected Recent Abstracts

Paul C. Trippier, Radhia Benmohammed, Donald R. Kirsch and Richard B. Silverman; Functionalized pyrazolones exhibiting N2 hydrogen bond donating ability protect against cytotoxicity in a cellular model of Amyotrophic Later Sclerosis. Abstracts of papers, 43rd ACS Central Regional Meeting, Dearborn, MI, USA. June 5-9, (2012), CERM-1282.

Paul C. Trippier, Yinan Zhang, Tian Chen, Radhia Benmohammed, Donald R. Kirsch, Robert J. Ferrante, Richard I. Morimoto and Richard B. Silverman; Amyotrophic Lateral Sclerosis therapeutics acting via a novel mode of action. ALS Drug Discovery Workshop, Washington DC, March 4th-7th 2012.

Paul C. Trippier, Tian Chen, Radhia Benmohammed, Donald R. Kirsch, Robert J. Ferrante, Richard I. Morimoto and Richard B. Silverman; Structural modification of neuroprotective small molecules for target identification studies: Towards possible Amyotrophic Lateral Sclerosis therapeutics. Abstracts of papers, 242nd ACS National Meeting, Denver, CO, United States. August 28th-September 1st (2011), MEDI-70.